Vaccinex Presents Updated Interim Results from a Phase 1b/2 Study of Pepinemab in Combination with Avelumab in Non-Small Cell Lung Cancer at the 2019 ASCO Annual Meeting
03 juin 2019 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
15 mai 2019 08h10 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s...
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
15 mai 2019 08h05 HE
|
Vaccinex, Inc.
Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2019 Enrollment in Phase 2 SIGNAL Huntington’s...
Vaccinex, Inc. Summary of Key Data Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
09 avr. 2019 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 09, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex, Inc. to Provide Clinical Data on Posters Presented at the 2019 Annual Meeting of the American Association for Cancer Research (AACR)
01 avr. 2019 08h00 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex, Inc. to Present at the Oppenheimer & Co. 29th Annual Healthcare Conference on March 19, 2019
13 mars 2019 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 13, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and...
Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
13 mars 2019 07h16 HE
|
Vaccinex, Inc.
Initial data from ongoing open label study of pepinemab (VX15/2503) in combination with avelumab in non-small cell lung cancer expected in 2Q 2019 Enrollment in cohort B of the Phase 2 SIGNAL...
Vaccinex, Inc. to Present Data on Its Anti-SEMA4D Compound at the American Association for Cancer Research Annual Meeting 2019
06 mars 2019 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., March 06, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
Vaccinex, Inc. Presented Previously Disclosed Data from Ongoing Phase 1/2 Trial of VX15/2503 (Pepinemab) in Huntington’s Disease (the “SIGNAL Trial”) at Cambridge Healthtech Institute’s 18th Annual PepTalk
17 janv. 2019 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. Announces Completion of Enrollment for Its “SIGNAL” Huntington’s Disease Trial
16 janv. 2019 08h30 HE
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) announced today that it has completed subject enrollment for the SIGNAL trial. SIGNAL is a Phase 2, multi-center,...